Anti-CD3 antibody as well as preparation method and application thereof

CN118922442APending Publication Date: 2024-11-08ABLINK BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280093675.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-03-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

It is difficult to develop effective antibodies against CD3 with existing technology, especially heavy chain single domain antibodies, resulting in difficulties in T cell activation and treatment of related diseases.

Method used

By isolating the heavy chain single domain antibody against CD3 from the phage display antibody library, the specific sequence is the VHH domain shown in Table a, including CDR1, CDR2 and CDR3, for preparing anti-CD3 antibodies or antibody-drug conjugation Drugs for the prevention and treatment of CD3-related diseases.

Benefits of technology

Successfully obtained a heavy chain single domain antibody that can specifically bind to CD3, achieving effective prevention and treatment of CD3-related diseases, and providing a new antibody-drug conjugate and its application method.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a single-domain antibody and application thereof. Specifically, the inventor of the invention successfully separates the antibody against CD3 from a phage display antibody library through continuous attempts. The antibodies of the invention can bind CD3 with high affinity, and can be used for treating or preventing diseases or for detection purposes.
Need to check novelty before this filing date? Find Prior Art

Description

An anti-CD3 antibody and its preparation method and use Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to an antibody that specifically binds to CD3, and a preparation method and use thereof. Background Art

[0002] CD3 is present on the surface of T cells and often binds tightly to the TCR to form a TCR-CD3 complex containing eight peptide chains. Together, they participate in T cell antigen recognition and signal transduction. Therefore, the development of CD3-based antibodies or molecules that can bind to CD3 is particularly important.

[0003] Camelids (such as camels and alpacas) can produce a type of heavy-chain antibody that naturally lacks light chains. It consists of only a heavy-chain variable region (VHH) and two conventional CH2 and CH3 regions, while possessing complete antigen-binding function. In particular, the VHH domain alone has antigen-binding activity comparable to that of the original heavy-chain antibody. It is the smallest known structure that can bind to the target antigen and is called a nanobody or heavy-chain single-domain antibody (these terms are used interchangeably in this article). Therefore, VHH represents a new direction in antibody development.

[0004] SUMMARY OF THE INVENTION

[0005] In view of this, the inventors of the present invention have continuously tried to effectively isolate a heavy chain single domain antibody against CD3 from a phage display antibody library. Specifically, the sequence of the heavy chain single domain antibody is shown in Table a below.

[0006] Table a: Heavy chain single domain antibody names and sequences

[0007]

[0008]

[0009]

[0010] Therefore, the present invention provides an anti-CD3 heavy chain single domain antibody.

[0011] The present invention provides a CD3 antibody (such as a conventional four-chain antibody, a domain antibody, a single-chain antibody, a VHH, a bispecific antibody or a multispecific antibody, etc.) or an antigen-binding fragment thereof, which comprises an anti-CD3 heavy chain single-domain antibody or three CDRs of a heavy chain single-domain antibody: CDR1, CDR2 and CDR3.

[0012] The present invention provides an antibody-drug conjugate (ADC), which comprises an anti-CD3 antibody or an antigen-binding fragment thereof.

[0013] In another aspect, the present invention relates to nucleic acid molecules encoding CD3 antibodies or ADCs, and expression vectors and host cells containing the nucleic acid molecules.

[0014] The present invention also relates to a pharmaceutical composition comprising the anti-CD3 antibody or antibody drug conjugate of the present invention.

[0015] The present invention also relates to a method for preparing an anti-CD3 antibody or an antibody-drug conjugate.

[0016] The present invention also relates to the use of the anti-CD3 antibody, antibody-drug conjugate and pharmaceutical composition, in particular, the use and method for preventing and / or treating diseases related to CD3.

[0017] Specifically, the present invention provides an anti-CD3 antibody or an antigen-binding fragment thereof, which comprises the CDRs shown in Table a or Table 1, for example, including three CDRs of VHH from h06 to h53: CDR1, CDR2 and CDR3.

[0018] Exemplarily, the anti-CD3 antibody or antigen-binding fragment thereof comprises three complementarity determining regions CDR1, CDR2 and CDR3 of VHH named h06, h08, h12, h18-h22, h25, h28, h30, h31, h33, h38, h40, h41, h53, preferably three CDRs of VHH of h18, h20, h21, h22, h28, h30 and h40, and most preferably three CDRs of VHH of h21 and h30.

[0019] The second aspect of the present invention provides a VHH or a variant thereof as shown in Table a or Table 1. Exemplarily, the variant includes a humanized variant or an identity variant.

[0020] The third aspect of the present invention provides an antibody-drug conjugate (ADC), which comprises an anti-CD3 antibody or an antigen-binding fragment thereof and a conjugated drug.

[0021] In a fourth aspect, the present invention provides a polynucleotide encoding a CD3 antibody or an antigen-binding fragment thereof or ADC, and an expression vector and a host cell containing the polynucleotide.

[0022] In a fifth aspect, the present invention provides a pharmaceutical composition comprising the anti-CD3 antibody or antigen-binding fragment thereof or antibody-drug conjugate of the present invention.

[0023] A sixth aspect of the present invention provides a method for preparing an anti-CD3 antibody or an antibody-drug conjugate.

[0024] The seventh aspect of the present invention provides uses of the anti-CD3 antibodies, antibody-drug conjugates, and pharmaceutical compositions, in particular uses and methods for preventing and / or treating CD3-related diseases.

[0025] The eighth aspect of the present invention further provides a fusion protein comprising the above-mentioned antibody or antigen-binding fragment.

[0026] Before successfully obtaining the antibody of the present invention, the inventors of the present invention tried dozens of times to obtain antibodies against CD3 according to normal immunization procedures, but all attempts ended in failure.

[0027] In the present disclosure, identity can refer to a sequence that has at least 80% sequence identity with a reference sequence or parent sequence and that does not completely lose the activity of the reference sequence or parent sequence. For example, the identity sequence of h06 refers to a sequence that has at least 80% sequence identity with the VHH of h06 and retains the ability to bind to CD3.

[0028] Exemplarily, the antibodies or antigen-binding fragments of the present disclosure can be selected from the following group: camel Ig, Ig NAR, Fab fragment, Fab' fragment, F(ab)'2 fragment, F(ab)'3 fragment, Fv, scFv, bis-scFv, (scFv)2, miniantibodies, diabodies, triabodies, tetrabodies, disulfide-stabilized Fv proteins, and single-domain antibodies (sdAb, nanobodies), bispecific antibodies, or trispecific antibodies, etc. For example, preferably, the antibody of the present invention is a conventional 4-chain antibody, a domain antibody, a single-chain antibody, a VHH, a bispecific antibody, or a multispecific antibody, or a humanized antibody thereof.

[0029] Exemplarily, the fusion protein described in the present invention may further comprise a tag sequence (e.g., Poly-His, Hemagglutinin, c-Myc, GST, Flag-tag, etc.) or an IgG1-Fc protein sequence, an additional epitope (e.g., other epitopes targeting CD3) or an additional antibody active fragment (e.g., antibodies or antibody active fragments targeting other epitopes of CD3 or the same epitope, or ligands that can bind to CD3).

[0030] For example, in the antibody-drug conjugates of the present disclosure, the drug is selected from the following: radiolabels, 32 P. 35 S, fluorescent dyes, electron-dense reagents, enzymes, biotin, streptavidin, digoxigenin, haptens, immunogenic proteins, nucleic acid molecules having a sequence complementary to a target, or a combination of any of the foregoing; or immunomodulatory compounds, anticancer agents, antiviral agents, antibacterial agents, antifungal agents, and antiparasitic agents, or a combination of any of the foregoing.

[0031] The polynucleotide is a polynucleotide encoding the antibody or antigen-binding fragment thereof described in the present disclosure, the fusion protein described in the present disclosure, or the ADC.

[0032] Exemplarily, the polynucleotide is a polynucleotide encoding h06 described in the present disclosure, or a degenerate sequence thereof, or a hybridization sequence under stringent conditions.

[0033] The present invention also provides a vector comprising the polynucleotide according to the present disclosure.

[0034] Exemplarily, the vector is an expression vector, such as a plasmid or a viral vector. The plasmid vector is, for example, a commercial plasmid vector or a modified vector thereof. The viral vector is, for example, a retroviral vector, such as a lentiviral vector, human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), Vesna-Medi virus (VMV), caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), simian immunodeficiency virus (SIV), and novel coronavirus.

[0035] The present invention also provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, ADC or fusion protein as described in the present disclosure, and optionally, a pharmaceutically acceptable carrier or excipient.

[0036] The present invention also provides a method for preparing the antibody or antigen-binding fragment thereof described in the present disclosure, which comprises introducing the vector described in the present disclosure into a host cell, such as a eukaryotic cell, such as HEK293 cell, CHO cell.

[0037] Illustratively, the method for preparing the antibody or antigen-binding fragment thereof of the present invention comprises the step of culturing the host cells (eg, eukaryotic cells, such as HEK293 cells, CHO cells) as described in the present disclosure, and optionally comprises further isolation and purification steps.

[0038] The present invention also provides the use of the following materials in the preparation of drugs for treating and / or preventing diseases related to CD3:

[0039] (a) an antibody or antigen-binding fragment thereof according to the present disclosure;

[0040] (b) the fusion protein described in the present disclosure;

[0041] (c) the antibody-drug conjugates of the present disclosure;

[0042] (d) The pharmaceutical compositions of the present disclosure.

[0043] Illustratively, the disease is one requiring activation of T cell function or for recruiting T cells, for example by means of bispecific antibodies (one directed against CD3 and the other against a tumor antigen).

[0044] The present invention also provides a method for treating and / or preventing diseases that require activation of T cell function, comprising administering an effective amount of (a) the antibody or antigen-binding fragment thereof described herein; (b) the fusion protein described herein; (c) the antibody-drug conjugate described herein; or (d) the pharmaceutical composition described herein to a subject.

[0045] The present invention also provides a method for detecting whether CD3 is expressed in a T cell sample, comprising the step of contacting the antibody or antigen-binding fragment thereof described in the present disclosure with the sample.

[0046] For example, in the process of detecting whether a sample contains T cells that highly express CD3, the antibody or antigen-binding fragment thereof described in the present disclosure can be first contacted with the sample, and then the immune reaction between the sample and the monoclonal antibody can be detected to determine whether the sample to be tested contains T cells that highly express CD3, for example, by indicating the detection result through enzyme-linked immunosorbent assay.

[0047] Alternatively, the method for detecting whether a sample contains T cells that highly express CD3 may include the following steps: contacting the sample to be tested with the antibody or antigen-binding fragment thereof described in the present disclosure; and detecting the immune reaction between the sample and the monoclonal antibody.

[0048] Furthermore, the present disclosure also provides the following application: use of the antibody or antigen-binding fragment thereof described in the present disclosure in preparing a sample for detecting whether T cells that highly express CD3 are present.

[0049] Furthermore, the present disclosure also provides the following application: use of the antibodies or antigen-binding fragments thereof described in the present disclosure in preparing products for detecting whether T cells with high CD3 expression are present in a sample, the products including but not limited to detection reagents, kits, chips or test strips.

[0050] The present disclosure also provides a detection product, which comprises the antibody or antigen-binding fragment thereof described in the present disclosure. The product includes but is not limited to a detection reagent, a kit, a chip or a test paper.

[0051] In the present disclosure, the detection may be for diagnostic purposes or non-diagnostic purposes.

[0052] For the antibodies or antigen-binding fragments thereof, fusion proteins, etc. described in the present disclosure, the present invention also contemplates variants thereof, such as identity sequences or humanized sequences thereof, etc. Exemplarily, the identity sequence refers to about 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1 or more, 99.2 or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more identity to the original sequence or reference sequence.

[0053] For the polynucleotides of the present invention, the present invention also contemplates degenerate sequences thereof or complementary sequences thereof or sequences that hybridize under stringent conditions. Exemplarily, the degenerate sequences thereof or complementary sequences thereof or sequences that hybridize under stringent conditions have a homology of about 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1 or more, 99.2 or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more to the original sequence or reference sequence. DETAILED DESCRIPTION

[0054] Unless otherwise indicated or defined, all terms used have ordinary meanings in the art, which will be understood by those skilled in the art.

[0055] Unless otherwise indicated, the terms "antibody" or "immunoglobulin" are used interchangeably. As used herein, they may refer to heavy chain antibodies, heavy chain single domain antibodies, or conventional four-chain antibodies, for example, full-length antibodies, individual chains thereof, single-chain antibodies (scFvs), and domains or fragments thereof (e.g., antigen-binding domains or fragments, such as VHH domains or VH / VL domains, respectively), or bispecific antibodies or multispecific antibodies.

[0056] In addition, the term "sequence" used herein (such as when using "immunoglobulin", "antibody", "heavy chain single domain antibody", "VHH", "protein" or "binding protein", etc.) generally includes both the relevant amino acid sequence and the nucleic acid sequence or nucleotide sequence encoding the sequence, unless otherwise specified herein or can be obviously determined by a person skilled in the art.

[0057] Examples of domain antibodies of the present invention may be single variable domains VH and VL (VH domain and VL domain) or "VHH" of the Camelidae family. "VHH" is also referred to as a heavy chain single domain antibody, a VHH domain, a VHH antibody fragment, and a VHH antibody. A VHH specifically binds to an antigen epitope without the need for additional antigen-binding domains. In the context of the present invention, the terms "heavy chain single domain antibody," "VHH domain," "VHH," "VHH domain," "VHH antibody fragment," and "VHH antibody" are used interchangeably.

[0058] The inventors of the present invention have obtained antibodies against CD3, such as VHHs, that can bind to CD3 through extensive unresolved screening. Optionally, the binding is specific. Further optionally, the antibodies against CD3 described in the present disclosure can bind to CD3.

[0059] In the present disclosure, the binding may be "specific binding." As will be appreciated by those skilled in the art, various experimental methods or means are readily apparent to those skilled in the art for testing binding and binding specificity. Methods for determining equilibrium association or equilibrium dissociation constants are known in the art. In many protein-protein interactions, some cross-reactivity or background binding may occur, but this does not impair the "specificity" of binding between antibodies or active fragments thereof. "Specific binding" may, for example, refer to the binding of an anti-CD3 antibody or antigen-binding fragment thereof (including antibody-drug conjugates thereof) described herein to CD3 with an affinity greater than background binding.

[0060] "Antigen (Ag)" refers to a compound, composition, or substance that can stimulate antibody production or a T cell response in an animal. In some embodiments of the present invention, the target antigen is an epitope of CD3. "Epitope" refers to the region of an antigen that binds to a binding agent. An epitope can be formed by contiguous amino acids or by non-contiguous amino acids that contribute to the tertiary structure of a protein.

[0061] "Single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present as a single polypeptide chain and in either connection orientation (e.g., VL-VH or VH-VL). Typically, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. In a preferred embodiment, the antibody-drug conjugates of the present invention comprise an antigen-specific binding domain of an antibody, which is, for example, an scFv and can be mouse, human, or humanized scFv. In a particular embodiment, the antigen-specific binding domain is a humanized scFv that binds to CD3.

[0062] Antibodies and Antibody Fragments:

[0063] Thus, the antibodies or antibody fragments of the present disclosure include, but are not limited to, polyclonal, monoclonal, bispecific, human, humanized or chimeric antibodies, single chain fragments (scFv), single variable fragments (ssFv), single domain antibodies (e.g., VHH fragments from nanobodies), Fab fragments, F(ab')2 fragments, fragments produced by Fab expression libraries, anti-idiotypic antibodies and epitope binding fragments or any combination thereof, provided that they have similar binding properties to the antibodies of the present disclosure, preferably comprising corresponding CDRs, or VH and VL regions as described herein. Minibodies and multivalent antibodies such as diabodies, triabodies, tetrabodies and pentabodies can also be used in the present invention.

[0064] As used herein, "antibody" generally refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or immunoglobulin gene fragments. When the term "antibody" is used, it may also be considered to refer to an "antibody fragment". Optionally, antibodies or antibody fragments can be chemically conjugated to or expressed as fusion proteins with other proteins or other proteins. In some embodiments, the antibodies or antigen-binding fragments of the present invention are included in multispecific antibodies, such as bispecific antibodies. Such multispecific antibodies can be produced by known methods, such as cross-linking two or more antibodies, antigen-binding fragments (e.g., scFv) of the same or different types. Exemplary methods for preparing multispecific antibodies include those described in PCT Patent Publication No. WO2013 / 163427, which are incorporated herein by reference in their entirety.

[0065] The affinity of a binding domain polypeptide of the invention and an antibody or antibody fragment can be readily determined using conventional techniques, for example by competitive ELISA (enzyme-linked immunosorbent assay), or using a surface plasmon resonance apparatus such as Biacore.

[0066] Humanized antibodies can be prepared using methods known in the art, comprising one or more CDRs of an antibody or antibody fragment of the invention or one or more CDRs derived from said antibody or antibody fragment, but comprising human FR regions. For example, a monoclonal antibody can generally be humanized using four steps: (1) determining the nucleotide and predicted amino acid sequences of the starting antibody light and heavy chain variable domains; (2) designing the humanized antibody, i.e., deciding which antibody framework regions to use in the humanization process; (3) performing humanization methods / techniques; and (4) transfection and expression of the humanized antibody. For example, see U.S. Patent No. 6,180,370.

[0067] The term humanized antibody means that at least a portion of the framework region of an immunoglobulin and a portion of an optional CDR region or other regions involved in binding are derived from or adjusted to human immunoglobulin sequences. Humanized, chimeric or partially humanized forms of mouse monoclonal antibodies can be prepared, for example, by recombinant DNA technology. By recombinant DNA technology, the CDR region of a non-human antibody is connected to a human constant region, and a humanized form of mouse antibodies can be produced (Queen et al., 1989; WO 90 / 07861). Alternatively, the monoclonal antibody used in the method of the present invention can be a human monoclonal antibody. Human antibodies can be obtained, for example, using phage display methods (WO 91 / 17271; WO 92 / 01047).

[0068] As used herein, humanized antibodies also refer to forms of non-human (e.g., murine, camel, llama, shark) antibodies that are specific chimeric immunoglobulins, immunoglobulin chains or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies, such as vHH), that contain minimal sequence derived from non-human immunoglobulin.

[0069] As used herein, a human or humanized antibody or antibody fragment refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and can be prepared using any technique known in the art for preparing antibodies. Human antibodies or fragments thereof can be selected by competitive binding experiments or other means to determine whether they have the same epitope binding specificity as a particular mouse antibody.

[0070] Variable region and CDR

[0071] The variable region of an antibody refers to the variable region of a single antibody light chain or the variable region of an antibody heavy chain or a combination thereof. The heavy chain variable region and the light chain variable region are each composed of four framework regions (FRs) connected by three complementary determining regions (CDRs), which are also called hypervariable regions. The CDRs in each chain are held together in close proximity by the FRs and, together with the CDRs from the other chains, contribute to the formation of the antigen binding site of the antibody.

[0072] CDRs are primarily responsible for binding to antigenic epitopes. There are many methods available for determining the boundaries of CDR amino acid sequences, such as Kabat et al., Sequences of Proteins of Immunological Interest, (5th ed., 1991, National Institutes of Health, Bethesda, MD, "Kabat" numbering scheme); Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 1997; 273:927-48 ("Chothia" numbering scheme); Lefranc et al. ("IMGT unique numbering for immunoglobulin and T cell receptor variable domain and Ig superfamily V-like domains," Dev. Comp. Immunol., 27:55-77, 2003; "IMGT" numbering scheme); or North, B, Lehmann A, Dunbrack RA new clustering of antibody CDR loops. Conformations: J. Mol. Biol. (2011), 406(2): 228-256. Alternative methods include, in addition to the above methods, new solutions developed with the advancement of bioinformatics. Although Kabat is the most commonly used method, CDRs can refer to CDRs defined by one or more methods, or by a combination of these methods.

[0073] Illustratively, the CDR sequences of VHHs determined according to the Kabat numbering scheme are shown in Table 1 below. The CDRs involved herein can be CDRs or CDR combinations determined by the same method, or CDRs or CDR combinations determined by different methods. For example, the antibodies of the present invention can contain HCDR1, HCDR2, and HCDR3 determined by any one of the methods of North, Kabat, Chothia, and IMGT. Those skilled in the art can freely select CDRs identified by different methods and can freely combine these CDRs. Table 1 below is an exemplary CDR determined according to the Kabat numbering scheme.

[0074] Table 1: CDRs identified according to the Kabat numbering scheme

[0075]

[0076]

[0077] In some embodiments, antibody provided by the present invention or its fragment comprise at least one CDR, at least two or at least three CDRs substantially identical with at least one CDR of the antibody of the present invention, at least two or at least three CDRs.In some embodiments, described at least one, two or three CDRs and at least one, two or three CDRs of the antibody of the present invention have at least about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98% or 99% homogeneity.Should be understood that for purposes of the present invention, conventionally retain binding specificity and / or overall activity, although activity degree can change (can be larger or smaller) compared with described antibody.

[0078] In certain embodiments, substitutions, insertions, or deletions may be present in one or more CDRs, as long as such changes do not substantially reduce the ability of the antibody to bind to the antigen. For example, conservative changes that do not substantially reduce binding affinity (e.g., conservative substitutions as provided herein) may be made in the CDRs. In certain embodiments of the variant VH and VL sequences provided above, each CDR may be unchanged or contain no more than one, two, or three amino acid substitutions, insertions, or deletions. For example, one, two, or three amino acids in a CDR sequence comprised in an antibody of the invention may be replaced, inserted, or deleted with amino acids of the same type and still retain the ability to bind to CD3.

[0079] For sites that can be mutated, reference can be made to Cunningham and Wells (1989) Science, 244: 1081-1085. This method for identifying residues or regions of antibodies that can be targeted for mutation is called "alanine scanning mutagenesis". In this method, a residue or a group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction between the antibody and the antigen is affected. Other replacements can be considered at amino acid positions that show functional sensitivity to initial replacement. Alternatively, or in addition, the contact points between the antibody and the antigen can be identified using the crystal structure of the antigen-antibody complex. Such contact residues and adjacent residues can be targeted as candidates for replacement. Variants can be screened to determine whether they contain desired properties.

[0080] Therefore, it should be clearly understood that, although the claims of this application document do not specifically limit the specific sequence of the mutated CDR, those skilled in the art can perform mutations based on the prior art (while retaining the activity of the antibody, for example, replacing, deleting or adding 1, 2 or 3 amino acid residues in the CDR region identified in the present invention) to discover mutated CDRs that can retain the activity of the antibody, and antibodies comprising mutated CDRs are obvious variants of the antibodies of the present invention and are therefore covered within the scope of protection of the present invention.

[0081] protein

[0082] "Protein," "polypeptide fragment," and "polypeptide" are used interchangeably unless otherwise indicated and are used in their conventional sense, i.e., as amino acid sequences. Proteins are not limited to a particular length; for example, they can comprise a full-length protein sequence or a fragment of a full-length protein, and can include post-translational modifications of the polypeptide (e.g., glycosylation, acetylation, phosphorylation, etc.), as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

[0083] In various embodiments, the polypeptides or proteins of the present invention contain a signal (or leader) sequence at the N-terminus of the protein that can direct protein transfer during or after translation. The polypeptides can be prepared using various well-known recombinant and / or synthetic techniques. For example, the fusion proteins of the present invention may contain a His tag to facilitate isolation and purification.

[0084] Nucleic Acids

[0085] As used herein, the term "polynucleotide" refers to mRNA, RNA, genomic RNA (gRNA), positive strand RNA (RNA(+)), negative strand RNA (RNA(-)), genomic DNA (gDNA), complementary DNA (cDNA), or recombinant DNA. Polynucleotides include single-stranded and double-stranded polynucleotides. Preferably, the polynucleotides of the present invention include polynucleotides or variants having at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or 100% sequence identity to any reference sequence described herein, typically wherein the variant retains at least one biological activity of the reference sequence.

[0086] Illustratively, the polynucleotides encoding antibodies or antigen-binding fragments thereof, antibody heavy chains, antibody light chains, antibody heavy chain variable regions, antibody light chain variable regions, CDRs, fusion proteins, etc. described in the present disclosure may be polynucleotides that hybridize therewith under stringent conditions and encode the active protein or polypeptide, or their complementary sequences.

[0087] The "stringent conditions" described herein can be any of low, medium, or high stringency conditions, with high stringency being preferred. For example, "low stringency conditions" can be 30°C, 5×SSC, 5×Denhardt's solution, 0.5% SDS, and 52% formamide; "medium stringency conditions" can be 40°C, 5×SSC, 5×Denhardt's solution, 0.5% SDS, and 52% formamide; and "high stringency conditions" can be 50°C, 5×SSC, 5×Denhardt's solution, 0.5% SDS, and 52% formamide. Those skilled in the art will appreciate that higher temperatures yield more homologous polynucleotides. Furthermore, those skilled in the art can select a desired degree of stringency based on a combination of factors that influence hybridization stringency, such as temperature, probe concentration, probe length, ionic strength, time, and salt concentration.

[0088] In addition, the hybridizable polynucleotide may also be, for example, a polynucleotide that has about 70% or more, 71% or more, 72% or more, 73% or more, 74% or more, 75% or more, 76% or more, 77% or more, 78% or more, 79% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 100% or more, 101% or more, 102% or more, 103% or more, 104% or more, 105% or more, 106% or more, 107% or more, 108% or more, 109% or more, 110% or more, 111% or more, 112% or more, 113% or more, 114% or more, 115% or more, 116% or more, 117% or more, 118% or more, 119% or more, 120% or more, 121% or more, 122% or more, 123% or more, 124% or more, 125% or more, 126% or more, 127% or more, 128% or more, 129% or more, 130% or more, 131% or more, 132% or more, 133% or more, 134% or more or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more identity.

[0089] Nucleotide sequence identity can be determined using the BLAST algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264-2268, 1990; Proc. Natl. Acad. Sci. USA 90:5873, 1993). Programs BLASTN and BLASTX based on the BLAST algorithm have been developed (Altschul SF, et al.: J Mol Biol 215:403, 1990). When using BLASTN for base sequence analysis, the parameters are score = 100 and wordlength = 12; when using BLASTX for amino acid sequence analysis, the parameters are score = 50 and wordlength = 3. When using BLAST and Gapped BLAST programs, the default parameters can be set using the system settings of each program.

[0090] Any of the various mature technologies known and available in the art can be used to prepare, manipulate and / or express polynucleotides. In order to express the desired polypeptide or protein, the nucleotide sequence encoding the polypeptide can be inserted into a suitable vector. Examples of vectors are plasmids, autonomously replicating sequences and transposable elements. Other exemplary vectors include, but are not limited to, plasmids, phagemids, cosmids, artificial chromosomes (e.g., yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1-derived artificial chromosomes (PACs)), bacteriophages (e.g., lambda phages or M13 phages) and animal viruses. Examples of animal virus vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, papovaviruses (e.g., SV40), and novel coronaviruses. An example of an expression vector is the pClneo vector (Promega) for expression in mammalian cells. In a particular embodiment, the coding sequence of the antibody or protein disclosed herein can be connected to this type of expression vector for expressing chimeric proteins in mammalian cells. "Control elements" or "regulatory sequences" present in expression vectors are non-translated regions of the vector (e.g., origin of replication, promoter, enhancer, translation initiation signal (SD sequence or Kozak sequence), introns, polyadenylation sequence, 5' and 3' untranslated regions) that interact with host cell proteins to carry out transcription and translation. The strength and specificity of such elements or sequences can vary. Depending on the vector system and host used, any number of suitable transcription and translation elements or sequences can be used, including broadly expressing promoters and inducible promoters.

[0091] About ADC

[0092] The basic structure of an antibody-drug conjugate can be "antibody-linker-drug active molecule" or "antibody-drug active molecule" (without a linker). For conjugates with a linker, the linker allows the drug to exhibit its effect on the target cell or virus, for example after separation from the antibody (e.g., by enzyme-mediated hydrolysis) and after the drug reaches the target cell or virus. The linker also plays a functional role by connecting the antibody and the drug. The efficacy and toxicity of the antibody-drug conjugate therefore depend in part on the stability of the linker, and therefore, the linker plays an important role in drug safety.

[0093] The linker of the antibody-drug conjugate can be roughly divided into non-cleavable or cleavable. Many non-cleavable linkers are connected to the antibody using thioether, which contains the cysteine ​​of the antibody. The drug of the side chain cannot be separated from the antibody in vivo, and the efficacy may also be reduced. In the case of the widely used thiol-maleimide method, the antibody-drug conjugate is unstable, which may cause the drug to separate from the conjugate before or after it reaches the target cell. The cleavable linker can be, for example, hydrolyzed by lysosomal enzymes. The cleavable linker can contain a disulfide bond, for example, including the cysteine ​​of the antibody. The disulfide linker that allows the dissociation via the thiol exchange reaction relies to some extent on the antibody-drug conjugate being taken into the target cell and exposing the disulfide to the cytosol as a reducing environment. However, because there are various types of thiols (such as albumin and glutathione) in the blood, the drug may be separated from the antibody before reaching its target.

[0094] In order to replace chemically unstable linkers, such as hydrazone and disulfide-based linkers, which have poor stability under physiological extracellular conditions, there is a need for linkers that are stable under physiological extracellular conditions. In addition, there is a need for linkers with high plasma stability to improve therapeutic applicability, because the drug should be released only into the cell targeted by the protein to which the drug is attached, rather than outside the cell.

[0095] New methods for preparing antibody-drug conjugates have been reported in the literature, for example, see US Patent Publication No. 2012 / 0308584. Further improvements are possible.

[0096] The antibodies of the present invention can also be conjugated to pharmaceutically active molecules on the antigen-binding domain side, such as lymphokines, affinity ligands, radioactive labels, immunomodulatory compounds, etc.

[0097] carrier

[0098] The term "vector" is used herein to refer to a nucleic acid molecule that is capable of transferring or transporting another nucleic acid molecule. The transferred nucleic acid is typically connected to, for example, inserted into, a vector nucleic acid molecule. A vector may include a sequence that directs autonomous replication in a cell, or may include a sequence sufficient to allow integration into the host cell DNA. Useful vectors include, for example, plasmids (e.g., DNA plasmids or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. Useful viral vectors include, for example, replication-defective retroviruses and lentiviruses.

[0099] As will be apparent to those skilled in the art, the term "viral vector" is broadly used to refer to nucleic acid molecules (e.g., transfer plasmids) or viral particles that mediate nucleic acid transfer, including virally derived nucleic acid elements that typically facilitate transfer or integration of nucleic acid molecules into the cellular genome. Viral particles typically include various viral components and sometimes host cell components in addition to the nucleic acid.

[0100] The term viral vector can refer to a virus or viral particle capable of transferring nucleic acid into a cell, or the nucleic acid itself. Viral vectors and transfer plasmids contain structural and / or functional genetic elements primarily derived from viruses. The term "retroviral vector" refers to a viral vector or plasmid containing structural and functional genetic elements, or portions thereof, primarily derived from a retrovirus.

[0101] In some embodiments, the genetically transformed cells are further transfected with a transposase that promotes the integration of the coding sequence into the genome of the transfected cells. In some embodiments, the transposase is provided as a DNA expression vector. However, in a preferred embodiment, the transposase is provided as an expressible RNA or protein so that the transposase is not expressed for a long time in the transgenic cells. For example, in some embodiments, the transposase is provided as an mRNA (e.g., an mRNA comprising a cap and a poly-A tail). Any transposase system can be used according to embodiments of the present invention. However, in some embodiments, the transposase is a salmonid Tel-like transposase (SB). In some embodiments, the transposase is an engineered enzyme with increased enzymatic activity. Some specific examples of transposases include, but are not limited to, SB 10, SB 11, or SB 100X transposases (see, e.g., Mates et al., 2009, Nat Genet. 41 (6): 753-61 or US9228180, which are incorporated herein by reference). For example, the method can include electroporating cells with mRNA encoding SB10, SB11, or SB100X transposase.

[0102] Sequence variants:

[0103] Sequence variants of the claimed nucleic acids, proteins, antibodies, antibody fragments (e.g., those defined by percent sequence identity) are also included within the scope of the present invention, which maintain similar binding properties of the present invention. These variants exhibit alternative sequences but retain substantially the same binding properties, such as target specificity, because the specific sequences provided are known to be functional analogs or functional analogs. Sequence identity refers to the percentage of identical nucleotides or amino acids when performing a sequence alignment.

[0104] As used herein, the term "sequence identity" refers to the degree of sequence identity on a nucleotide-by-nucleotide or amino acid-by-amino acid basis over a comparison window. Thus, the "percentage of sequence identity" can be calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions where the same nucleic acid base (e.g., A, T, C, G, I) or the same amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, He, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) is present in the two sequences to produce the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to obtain the percentage of sequence identity. Nucleotides or polypeptides having at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any reference sequence described herein are included, typically wherein the polypeptide variant retains at least one biological activity of the reference polypeptide.

[0105] Those of ordinary skill in the art will appreciate that, due to the degeneracy of the genetic code, there are many nucleotide sequences encoding polypeptides or proteins as described herein. Some of these polynucleotides have minimal homology or sequence identity to the nucleotide sequence of any natural gene. Nevertheless, the present invention specifically contemplates polynucleotides that vary due to differences in codon usage. Deletions, substitutions, and other variations that fall within the sequence identity are also encompassed by the present invention.

[0106] Protein sequence modifications that can occur by replacement are also included within the scope of the present invention. Replacement, as defined herein, is a modification of the amino acid sequence of a protein whereby one or more amino acids are replaced by the same number of (different) amino acids, thereby producing a protein containing an amino acid sequence different from that of the primary protein. Replacements can be made that preferably do not significantly change the function of the protein. As with additions, replacements can be natural or artificial. It is well known in the art that amino acid replacements can be made without significantly changing the function of a protein. This is especially true when the modification involves a "conservative" amino acid replacement, where one amino acid is replaced with another amino acid having similar properties. This type of "conservative" amino acid can be a natural or synthetic amino acid that can be replaced but will not significantly affect the structure and function of the protein due to size, charge, polarity, and conformation. Typically, many amino acids can be replaced by conservative amino acids without adversely affecting the function of the protein.

[0107] In general, the nonpolar amino acids Gly, Ala, Val, Ile, and Leu; the nonpolar aromatic amino acids Phe, Trp, and Tyr; the neutral polar amino acids Ser, Thr, Cys, Gln, Asn, and Met; the positively charged amino acids Lys, Arg, and His; and the negatively charged amino acids Asp and Glu represent conservative amino acid groups. This list is not exhaustive. For example, it is well known that Ala, Gly, Ser, and sometimes Cys can substitute for one another, even though they belong to different groups.

[0108] Substitution variants remove at least one amino acid residue in the antibody molecule and insert a different residue in its place. For the occurrence of substitution mutagenesis, the positions of greatest interest include the hypervariable regions, but FR changes are also contemplated. If such substitutions result in changes in biological activity, larger amounts of changes can be introduced and the products screened.

[0109] Compositions and formulations

[0110] The compositions of the present invention may comprise one or more polypeptides, antibodies or antigen-binding fragments thereof, polynucleotides, vectors comprising the polynucleotides, etc. as contemplated herein. Compositions include, but are not limited to, pharmaceutical compositions. A "pharmaceutical composition" refers to a composition formulated in a pharmaceutically acceptable or physiologically acceptable solution that is administered to a cell or animal alone or in combination with one or more other therapeutic modalities. It should also be understood that the compositions of the present invention may also be administered in combination with other agents, such as cytokines, growth factors, hormones, small molecules, chemotherapeutic agents, prodrugs, drugs, antibodies, or other various pharmaceutically active agents, if desired. There is virtually no limit to the other components that may be included in the composition, provided that the additional components do not adversely affect the ability of the composition to deliver the intended therapy.

[0111] The term "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit / risk ratio.

[0112] As used herein, "pharmaceutically acceptable carrier, diluent or excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, surfactant or emulsifier that has been approved by the U.S. Food and Drug Administration or the China Food and Drug Administration for use in humans or livestock. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; gum tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable oils and fats, paraffins, silicones, bentonite, silicic acid, zinc oxide; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and any other compatible substances used in pharmaceutical formulations.

[0113] In particular embodiments, the compositions of the present invention comprise an amount of an active substance of the present invention. As used herein, the term "amount" refers to an "effective amount" of an active substance of the present invention (e.g., an antibody or antigen-binding fragment thereof, ADC, carrier, etc.) that achieves a beneficial or desired prophylactic or therapeutic or detection result (including clinical results and detection effects).

[0114] A "prophylactically effective amount" refers to an amount of genetically modified therapeutic cells effective to achieve the desired prophylactic outcome. Typically, but not necessarily, a prophylactic dose is less than a therapeutically effective amount because a prophylactic dose is used in a subject prior to or at an early stage of disease. The term prevent does not necessarily refer to completely inhibiting or preventing a particular medical condition. The term prevent also refers to reducing the risk of a medical condition developing or worsening its symptoms.

[0115] A "therapeutically effective amount" can vary depending on various factors, such as disease state, age, sex, and weight of the individual. A therapeutically effective amount is also an amount in which the beneficial effects of treatment outweigh any toxic or deleterious effects. The term "therapeutically effective amount" includes an amount that is effective to "treat" a subject (e.g., a patient). When a therapeutic amount is indicated, the exact amount to be administered can be determined by a physician taking into account individual differences in age, weight, tumor size, degree of infection or metastasis, and the condition of the patient (subject).

[0116] The pharmaceutical composition of the present invention may comprise: a buffer, such as neutral buffered saline, phosphate buffered saline, etc.; a carbohydrate, such as glucose, mannose, sucrose or dextran, mannitol; a protein; a polypeptide or an amino acid (such as glycine); an antioxidant; a chelating agent (such as EDTA) or glutathione; an adjuvant, such as aluminum hydroxide; and a preservative. The composition of the present invention is preferably formulated for parenteral administration, such as intravascular (intravenous or intraarterial), intraperitoneal or intramuscular administration, or for oral administration.

[0117] Exemplarily, the pharmaceutical composition of the present invention can be a liquid pharmaceutical composition, such as a solution, a suspension or other similar form, which can include one or more of the following: a sterile diluent (e.g., water for injection), a saline solution (preferably physiological saline, Ringer's solution, isotonic sodium chloride), a fixed oil (e.g., a synthetic monoglyceride or diglyceride that can be used as a solvent or suspension medium), polyethylene glycol, glycerol, propylene glycol or other solvents; an antibacterial agent, such as benzyl alcohol or methyl paraben; an antioxidant, such as ascorbic acid or sodium bisulfite; a chelating agent, such as ethylenediaminetetraacetic acid; and a buffer, such as acetate, citrate or phosphate, and an agent for regulating osmotic pressure, such as sodium chloride or glucose. Parenteral formulations can be packaged in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Injectable pharmaceutical compositions are preferably sterile.

[0118] In a particular embodiment, the composition of the invention comprises an effective amount of the active ingredient alone or in combination with one or more therapeutic agents.Thus, the antibodies or antigen-binding fragments thereof of the invention can be administered alone or in combination with other known antiviral treatments.

[0119] treat

[0120] As used herein, the terms "individual" and "subject" are generally used interchangeably and refer to any animal that exhibits symptoms of a disease, disorder, or condition that can be treated with the therapeutic agents and methods disclosed elsewhere herein. Typical subjects include experimental animals (e.g., mice, rats, rabbits, or guinea pigs), farm animals, and livestock or pets (e.g., cats or dogs). Non-human primates are included, and preferably human patients are included. Typical subjects include human patients infected with or at risk of infection with the novel coronavirus.

[0121] As used herein, "treating" includes any beneficial or desired effect on the symptoms or pathology of a disease or pathological condition, and may include even the smallest reduction in one or more measurable markers of the disease or condition being treated. Treatment may optionally involve the alleviation or amelioration of the symptoms of the disease or condition, or the delay of the progression of the disease or condition. "Treatment" does not necessarily mean complete eradication or cure of the disease or condition or its associated symptoms.

[0122] As used herein, "prevent" refers to methods of preventing, inhibiting, or reducing the likelihood of the occurrence or recurrence of a disease or condition. It also refers to delaying the onset or recurrence of a disease or condition, or delaying the onset or recurrence of symptoms of a disease or condition. As used herein, "prevent" and similar terms also include reducing the intensity, impact, symptoms, and / or burden of a disease or condition prior to the onset or recurrence of the disease or condition.

[0123] The administration of the compositions of the present invention can be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, blood transfusion, implantation or transplantation. In a preferred embodiment, the compositions are administered parenterally. As used herein, the phrase "parenteral administration" refers to modes of administration other than enteral and topical administration, typically by injection, including but not limited to intravascular, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardial, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0124] The terms and expressions employed herein are used as descriptive rather than limiting terms, and nothing in the use of such terms and expressions is intended to exclude any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the claimed invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modifications and variations of the concepts disclosed herein may be employed by those skilled in the art, and such modifications and variations are considered to be within the scope of the invention as defined by the appended claims.

[0125] To more clearly illustrate the present invention, it is now described in detail with reference to the following examples. However, these examples are merely illustrative descriptions of the present invention and are not to be construed as limiting the present application.

[0126] Example 1: Antigen preparation and alpaca immunization

[0127] 1. Expression and preparation of human CD3D&3E and CD3G&3E heterodimeric recombinant proteins

[0128] DNA sequences corresponding to human CD3 Delta (CD3D), CD3 Epsilon (CD3E, with a 6XHis tag attached to the C-terminus), and CD3 Gamma (CD3G) proteins were synthesized and cloned into the eukaryotic expression vector pFcIG with a secretion signal peptide. The cells were then electroporated into Escherichia coli trans5α and the correct recombinant plasmids were obtained by sequencing the single clones after ampicillin selection. The host bacteria containing the recombinant plasmids were then expanded and sterile, endotoxin-free plasmids were obtained using an endotoxin removal kit. HEK293F cells were transfected with CD3D and CD3E plasmids or CD3G and CD3E plasmids at a 1:1 ratio using a suspension cell transfection reagent. After 5 days of expansion in serum-free medium, the supernatant was collected and the human CD3D & 3E or human CD3G & 3E heterodimeric recombinant proteins were isolated and purified using Ni-NTA resin. In addition, HEK 293F cells were transfected with CD3E plasmid alone and cultured in serum-free medium for 5 days. The supernatant was collected and human CD3E recombinant protein was separated and purified using Ni-NTA resin.

[0129] 2. Alpaca Immunity

[0130] Human CD3D&3E or human CD3G&3E heterodimer recombinant protein was injected into multiple masses at the subcutaneous and intramuscular points of the alpaca's neck and back, and the absorption of the subcutaneous injection masses was tracked to confirm correct immunization (a total of 4 immunizations).

[0131] 3. Serum processing and titer testing

[0132] One week after the fourth immunization, 50 ml of peripheral blood was collected, and serum and lymphocytes were separated. CD3E antigen was coated in a 96-well ELISA plate, and serum antibody titers were determined by ELISA. Antiserum titers are shown in Table 2.

[0133] Table 2 Alpaca 4 immune serum titer (ELISA)

[0134]

[0135] Example 2: Construction and screening of phage display immune antibody library

[0136] Since the titer of the fourth serum was >1:32000, it indicated that there were high-affinity antibodies against human CD3E in the serum. A phage display immune antibody library was further constructed, and a positive monoclonal anti-human CD3E nanobody was obtained through biological screening.

[0137] 1. Collect blood from alpacas after the fourth immunization and separate PBMCs; take 2×10 7PBMCs were cultured and total RNA was extracted using an RNA extraction kit; an appropriate amount of RNA (e.g., 3-5 μg) was taken and cDNA was obtained using an RT-PCR reverse transcription kit.

[0138] 2. Obtain the heavy chain variable region sequences of IgG2 and IgG3 (the heavy chain variable region VHH of nanobodies) in steps by nested PCR or obtain the heavy chain variable region sequences of IgG1, IgG2 and IgG3 (the heavy chain variable region VH of conventional antibody IgG1 and the heavy chain variable region VHH of nanobodies IgG2 and IgG3) by one-step PCR.

[0139] 3. Insert the heavy chain variable region sequence into the linearized phagemid vector pShort treated with enzyme digestion by homologous recombination or enzyme ligation to obtain the recombinant vector; after purification and recovery, transform the super competent SS320 cells (containing helper phage M13K07); resuspend the transformed bacterial solution in SOC medium and activate it for 1 hour; take a small amount of bacterial solution for 10-fold serial dilution, select the appropriate dilution titer, and culture in LB / tet 10 and LB / Carb 50 The culture plate was coated and placed in a 37°C biochemical incubator overnight. The next day, the remaining bacterial liquid was used to calculate the storage capacity. The remaining bacterial liquid was transferred to a large volume of 2YT / Carb 50 / Kan 25 The cells were placed in a liquid culture medium on a shaker at 37°C for overnight culture. The supernatant was harvested the next day, and 1 / 4 volume of PEG / NaCl solution was added to precipitate the phages. An appropriate amount of PBT solution was then taken to resuspend and dilute to the required concentration to obtain the phage display immune antibody library (stored at -80°C for future use).

[0140] 4. Calculate LB / Carb 50 The number of clones on the plate and the calculated library capacity are: Alpaca #1 library 1 (nested PCR): 3.35×10 9 ; Alpaca #1 library 2 (one-step method): 6.12×10 9 ; Alpaca #2 library 1 (nested PCR): 1.64×10 9 Alpaca #2 library 2 (one-step method): 5.58×10 9 20 single clones were randomly picked from each plate for sequencing, and all of them were clones with correct VHH insertion.

[0141] 5. Combine the four antibody libraries constructed by alpacas into one large library for subsequent biological screening.

[0142] Example 3: Screening of antibody library

[0143] 1. Add 5 μg / mL of human CD3D&3E or human CD3G&3E antigen recombinant protein to a 96-well plate (100 μl / well) and coat overnight at 4°C. 10 Streak the plate and incubate overnight at 37°C;

[0144] 2. The next day, from the overnight 2YT / Tet 10 Pick up NEB5αF' monoclonal clone from the plate and add it to 3ml 2YT / Tet 10 In liquid culture medium, shake and grow the bacteria at 37℃ until OD 600 =0.8;

[0145] 3. Meanwhile, remove the antigen supernatant from the 96-well plate, add 200 μL of 1% BSA to each well for blocking, and add 200 μL of 1% BSA to the blank well as a negative control well, and place it on a 3D rotary shaker at room temperature for 2 hours; then, remove the supernatant from the protein wells and control wells, wash with 200 μL of PT, add 100 μL of phage antibody library to each, and place it on a 3D rotary shaker at room temperature for 2 hours; remove the supernatant from the protein wells and control wells, wash with 200 μL of PT; add 100 μL of 100 mM HCl to the wells and place them at room temperature for 5 minutes; aspirate the supernatant, add it to a 1.5 ml centrifuge tube, and neutralize it with 1 M Tris-HCl.

[0146] 4. Add the mixture obtained in step 3 to a centrifuge tube containing 1 mL of NEB5αF' bacteria, shake at 37°C, and culture for 1 hour; take 20 μL of the culture medium in the centrifuge tube and dilute it to an appropriate multiple, and add it to LB / Carb 50 The culture plate was coated and placed in a 37°C biochemical incubator overnight. The titer and enrichment were calculated the next day. 1 μL of helper phage M13K07 (final concentration of 10 10 / mL), shake at 37 ° C, culture for 1 hour; transfer the above culture medium into 35mL 2YT / Carb 50 / Kan 25 The cells were placed in a culture medium, placed in a shaker, and cultured overnight at 37°C. Phages were collected to form an antibody library for each round.

[0147] 5. Repeat the above steps for 3-5 rounds until phage enrichment occurs. 50 Enrichment was considered successful when the number of colonies on the culture plate was 10 times greater than that in the negative control wells. In this experiment, after the third round of screening, the number of colonies in the antigen-binding wells was 100 times greater than that in the negative control wells, indicating successful enrichment. Phage-ELISA was then performed to select high-affinity positive clones.

[0148] Example 4: Phage-ELISA identification of positive clones and sequencing

[0149] 1. In a 96-deep-well plate, add 400 μL 2YT / Carb to each well. 50 / Kan 25 / M13K07 medium; obtained from enriched LB / Carb 50 Single clones were picked from the culture plate, transferred to a 96-deep-well plate, placed on a shaker, and cultured overnight at 200 rpm and 37°C. The supernatant was the phage produced by each single clone and centrifuged the next day.

[0150] 2. At the same time, dilute the human CD3D&3E or human CD3G&3E antigen recombinant protein to 1 μg / mL, add 50 μL / well to the ELISA 96-well plate, and place in a 4°C refrigerator overnight;

[0151] 3. The next day, invert the ELISA plate to remove the supernatant. Then, block the plate with 100 μL of 1% BSA in each well. Add 100 μL of 1% BSA to the blank wells as negative controls. Incubate at room temperature for 1 hour. After blocking, wash the antigen wells and negative control wells with PT solution, then add 50 μL of supernatant from the 96-well plate and incubate at room temperature for 2 hours. Add the supernatant from each monoclonal clone to one antigen well and one negative control well.

[0152] 4. After binding is complete, wash the ELISA plate with PT solution, add 50 μL of HRP-M13 antibody, and incubate at room temperature for 1 hour. After washing with PT solution and PBS solution, add 50 μL of TMB and incubate at room temperature for 5 minutes. Then, add 50 μL of 1 M phosphoric acid to terminate the reaction. Measure the absorbance at 450 nm using a microplate reader. If the OD value is >4, the microplate reader will indicate overflow.

[0153] 5. The monoclonal clones corresponding to the antigen well OD value > 0.5 and the negative control well OD value < 0.2 were identified as positive clones with high affinity and subjected to monoclonal DNA sequencing; the obtained unique sequences are shown in Table 3.

[0154] Table 3 Phage ELISA positive clones

[0155]

[0156]

[0157] Example 5: Eukaryotic expression of nanobodies (VHH-Fc fusion protein) and affinity identification

[0158] The 17 sequences screened in Example 4 were eukaryotically expressed to study their affinity to the antigen recombinant protein and antigen-overexpressing cell lines.

[0159] 1. Amplify the VHH fragments of these sequences by PCR and insert them into the eukaryotic expression vector pFcIG containing a partial human IgG1 fragment (hinge+CH2+CH3) using homologous recombination or enzyme ligation. Electrophoretically transform the fragments into the E. coli trans5α host bacteria, select with ampicillin, and sequence the single clones to obtain the correct recombinant plasmid. Expand the host bacteria containing the recombinant plasmid and use an endotoxin removal kit to obtain a sterile, endotoxin-free plasmid.

[0160] 2. HEK293F cells were cultured in serum-free medium and transfected with the recombinant expression plasmid using polyplus suspension cell transfection reagent for expression. Feeds were added 24 and 72 hours after transfection. On day 5, the supernatant was collected and purified using Protein A agarose resin. The antibody protein was then exchanged and stored in 50 mM Tris-HCl, 200 mM NaCl (pH 8). Calculations revealed that the yield of the VHH-FC fusion protein for all 17 sequences ranged from 6 to 84 mg / L. SDS-PAGE electrophoresis confirmed that the VHH-FC bands for all 17 sequences were of normal size and >95% purity.

[0161] 3. Using ELISA, the affinity of 17 VHH-Fc fusion proteins for recombinant human CD3E antigen was determined: 1) 100 ng of recombinant human CD3E protein (his tag) was added to a 96-well ELISA plate and coated overnight at 4°C. 2) The VHH-Fc fusion protein was diluted to various concentrations (0.01-10 μg / ml) and reacted with the antigen in an ELISA. The absorbance at 450 nm was measured using a microplate reader. The results are shown in Table 4. The ELISA EC50 values ​​for the 10 VHH-Fc fusion proteins for recombinant human CD3E antigen were <80 μg / mL (1 μM).

[0162] 4. Using ELISA, determine the affinity of the 10 sequences obtained in step 3 with an EC50 value <80 μg / mL for monkey and mouse CD3D&3E antigen recombinant proteins: 1) Add 100 ng of monkey CD3D&3E and mouse CD3D&3E recombinant proteins (his tag) to a 96-well ELISA plate and coat overnight at 4°C. 2) Dilute the VHH-Fc fusion proteins to varying concentrations (0.01-10 μg / ml) and perform ELISA reactions with the antigens. Measure the absorbance at 450 nm using a microplate reader. The results are shown in Table 4. The experimental results demonstrate that the VHH-Fc fusion proteins of sequences h21 and h30 cross-bind with the monkey and mouse CD3D&3E antigen recombinant proteins.

[0163] Table 4 Binding affinity of VHH-FC fusion protein to human CD3E (ELISA EC50)

[0164]

[0165] 5. Use flow cytometry to detect the affinity of the 10 sequences with EC50 < 80 μg / mL obtained in step 3 to the human CD3 overexpressing cell line Jurkat: 1) Take 0.3×10 6 1) Jurkat cells were washed twice with PBS and then resuspended in 100 μL PBS; 2) incubated with 10 μg / ml and 50 μg / ml VHH-FC fusion protein for 1 hour; 3) washed three times with PBS, resuspended in 100 μL PBS, and 0.2 μg / ml FITC-labeled anti-human Fc antibody was added and incubated for 1 hour; 4) washed three times with PBS, resuspended in 300 μL PBS, and fluorescence was detected by flow cytometry. The results are shown in Table 5.

[0166] The experimental results showed that VHH-FC fusion proteins with sequences h18, h20, h21, h22, h28, h30 and h40 could bind to Jurkat cell lines.

[0167] Table 5 Binding affinity of VHH-FC fusion proteins to Raji cells (FACS)

[0168] No. Antibody concentration 10ug / mL Antibody concentration 50ug / mL2 Antibody (control) 1.13% 1.13% h0 8 2.61% 3.42% h12 3.04% 8.15% h18 6 7.60% 85.40% h20 9 1.90% 95.07% h21 6 5.80% 80.87% h22 5.46% 40.29% h28 3.77% 39.00% h30 8 9.43% 95.77% h38 2.70% 4.47% h40 6 7.50% 90.07%

[0169] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. An anti-CD3 antibody and variants thereof, or antigen-binding fragments thereof, wherein the anti-CD3 antibody comprises three complementary determining regions (CDR1, CDR2, and CDR3) of a VHH designated h06, h08, h12, h18-h22, h25, h28, h30, h31, h33, h38, h40, h41, or h53, 2. The antibody and variants thereof according to claim 1, or antigen-binding fragments thereof, wherein the variant is a humanized variant or an identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%) variant.

3. The antibody and variant thereof according to any one of claims 1 to 2, or an antigen-binding fragment thereof, which is selected from camel Ig, Ig NAR, Fab fragment, Fab' fragment, F(ab)'2 fragment, F(ab)'3 fragment, Fv, scFv, bi-scFv, (scFv)2, miniantibody, double-chain antibody, three-chain antibody, four-chain antibody, disulfide bond-stabilized Fv protein and single domain antibody (sdAb, nanobody), bispecific antibody or trispecific antibody, preferably VHH named h06, h08, h12, h18-h22, h25, h28, h30, h31, h33, h38, h40, h41, h53 or a humanized variant thereof.

4. A fusion protein comprising the antibody and variant thereof, or an antigen-binding fragment thereof according to any one of claims 1 to 3.

5. The fusion protein according to claim 4, further comprising a tag sequence (e.g., Poly-His, Hemagglutinin, c-Myc, GST, Flag-tag, etc.) or an IgG1-Fc protein sequence, or an additional epitope (e.g., an epitope directed against or other epitope different from CD3) or an additional antibody active fragment (e.g., an antibody or antibody active fragment directed against other epitopes or the same epitope of CD3, or a ligand capable of binding to CD3).

6. An antibody-drug conjugate comprising the antibody or variant thereof according to any one of claims 1 to 5, or an antigen-binding fragment thereof.

7. The antibody-drug conjugate of claim 6, wherein the drug is selected from the group consisting of: a radiolabel, 32 P. 35 S, fluorescent dyes, electron-dense reagents, enzymes, biotin, streptavidin, digoxigenin, haptens, immunogenic proteins, nucleic acid molecules having a sequence complementary to a target, or a combination of any of the foregoing; or immunomodulatory compounds, anticancer agents, antiviral agents, antibacterial agents, antifungal agents, and antiparasitic agents, or a combination of any of the foregoing.

8. An isolated polynucleotide expressing an antibody or antigen-binding fragment thereof, characterized in that: The polynucleotide can express the antibody and variant thereof, or antigen-binding fragment thereof, according to any one of claims 1 to 3; the polynucleotide can express the fusion protein according to any one of claims 4 to 5; the polynucleotide can express the antibody-drug conjugate according to any one of claims 6 to 7.

9. A vector comprising the polynucleotide according to claim 8, preferably a plasmid vector.

10. A host cell comprising the polynucleotide according to claim 8 or the vector according to claim 9, preferably, the host cell is a eukaryotic cell.

11. A pharmaceutical composition comprising the antibody and variant thereof according to any one of claims 1 to 3, or an antigen-binding fragment thereof, the fusion protein according to any one of claims 4 to 5, the antibody-drug conjugate according to any one of claims 6 to 7, and optionally, a pharmaceutically acceptable carrier.

12. Use of the antibody and variant thereof according to any one of claims 1 to 3, or an antigen-binding fragment thereof, the fusion protein according to any one of claims 4 to 5, or the antibody-drug conjugate according to any one of claims 6 to 7 in the preparation of a medicament for treating and / or preventing CD3-related diseases.

13. A method for treating and / or preventing CD3-related diseases and related symptoms, comprising administering an effective amount of the antibody and variant thereof, or antigen-binding fragment thereof, according to any one of claims 1 to 3, the fusion protein according to any one of claims 4 to 5, the antibody-drug conjugate according to any one of claims 6 to 7, or the pharmaceutical composition according to claim 11 to a subject.

14. A method for detecting whether a sample contains T cells that highly express CD3, comprising the step of contacting the sample with the antibody or variant thereof, or antigen-binding fragment thereof, according to any one of claims 1 to 3, or the fusion protein according to any one of claims 4 to 5, wherein the detection can be for diagnostic or non-diagnostic purposes.

15. A detection product comprising the antibody and variant thereof, or an antigen-binding fragment thereof according to any one of claims 1 to 3.

16. The detection product according to claim 15, wherein the product is selected from one or more of a detection reagent, a kit, a chip or a test paper.